OPRX - OptimizeRx Non-GAAP EPS of $0.07 beats by $0.03 revenue of $15.1M beats by $0.08M
- OptimizeRx press release ( NASDAQ: OPRX ): Q3 Non-GAAP EPS of $0.07 beats by $0.03 .
- Revenue of $15.1M (-6.3% Y/Y) beats by $0.08M .
- Gross profit in the third quarter of 2022 increased 4% year-over-year to $9.4 million.
- Cash, cash equivalents and short-term investments totaled $78.8 million as of September 30, 2022 as compared to $84.7 million as of December 31, 2021.
- Based on third quarter results, the Company is reiterating its full year financial outlook for 2022 for net revenue to be between $62 million and $68 million vs $64.05M Consensus
For further details see:
OptimizeRx Non-GAAP EPS of $0.07 beats by $0.03, revenue of $15.1M beats by $0.08M